ThursdayMar 16, 2017 1:58 pm

ChineseInvestors.com (CIIX) Helping Treat Patients with Amyotrophic Lateral Sclerosis

Late February, a study was released (http://nnw.fm/R2CEp) reviewing evidence that supports the use of cannabinoids to treat Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. Also known as Lou Gehrig’s disease, ALS is a fatal illness that attacks the nerve cells that control voluntary muscles such as those in the face, arms, legs, and others. Currently, ALS is treated with riluzole, a drug that controls neuronal signaling, but this drug does not cure the disease and can only slightly increase the chance of survival. With more effective therapeutic options…

Continue Reading

ThursdayMar 16, 2017 1:15 pm

InMed Pharmaceuticals (IMLFF) Lead Product Candidate Targeting Rare, Incurable Skin Disease

With a prevalence of 20 per million newborns in the United States, and an estimated 500,000 patients worldwide, epidermolysis bullosa is a group of rare inherited skin diseases that range in severity from mild to lethal and have no currently approved or known cure or treatment. The condition was brought to the public attention in the early 2000s, and, since then, efforts to find a cure have not born fruit, with most research and development focusing instead on addressing the symptoms, such as reducing blistering and swelling and preventing wounds and pain. However, a new product currently in development by…

Continue Reading

ThursdayMar 16, 2017 8:30 am

Unique Cannabis-Pharma Companies Trailblazing the Medical Cannabis Industry

The cannabis industry has swiftly turned into a multi-billion dollar opportunity. In the United States, this market’s massive growth potential is being recognized as new states legalize marijuana for medical or recreational use. Industry experts forecast the U.S. cannabis market rounding $7 billion in 2016, while the annual sale of state-legal cannabis products is forecast to exceed $20 billion by 2020. Within this flourishing market, cannabis-pharma companies like India Globalization Capital (IGC) (IGC Profile), Zynerba Pharmaceuticals, Inc. (ZYNE), OWC Pharmaceutical Research Corp. (OWCP), Insys Therapeutics, Inc. (INSY) and GW Pharmaceuticals plc (GWPH) are carving lanes of unprecedented opportunities in the…

Continue Reading

WednesdayMar 15, 2017 12:30 pm

22nd Century Group, Inc. (NYSE: XXII) Starts Presentation at 29th Annual ROTH Conference

22nd Century (NYSE: XXII) is a plant biotech company providing technology that allows for the level of nicotine and other nicotinic alkaloids in tobacco plants and the level of cannabinoids in cannabis plants to be decreased or increased through genetic engineering and plant breeding. The company develops smoking cessation products and modified risk tobacco products for smokers who are unable or unwilling to quit smoking and who may be interested in cigarettes, which reduce exposure to nicotine or to certain tobacco smoke toxins and/or pose a lower health risk than conventional cigarettes. For more information, visit the company’s website at www.xxiicentury.com.…

Continue Reading

WednesdayMar 15, 2017 8:30 am

“No-Touch” Approach Reduces Risk as Public Companies Tap Explosive Growth of Cannabis Industry

The marijuana industry is the new investing frontier. As a result of last November’s elections, eight states and the District of Columbia now allow the recreational use of marijuana, while another 28 states permit its use for medicinal purposes. In what has been touted as the fastest-growing industry in the U.S., investment opportunities in the cannabis space appear boundless. Companies like Singlepoint, Inc. (SING) (SING Profile), American Cannabis Company Inc. (AMMJ), General Cannabis Corp. (CANN), The Scotts Miracle-Gro Company (SMG) and Terra Tech Corp. (TRTC) are all employing a “no-touch” approach to their cannabis business models. By creating business models…

Continue Reading

WednesdayMar 15, 2017 8:30 am

Biotech Innovations Drive Cannabinoid-Based Pharmaceutical Market Growth

As the medical marijuana market continues to grow, so does the number of biotech companies expanding their research into the development of innovative cannabinoid-based pharmaceuticals and delivery systems. It is estimated that the U.S. consumer market for cannabinoid pharmaceuticals will increase exponentially in upcoming years, exceeding $50 billion by 2029, according to Statista. This doesn’t appear to be a lofty forecast, given the prominence this market segment has gained by the sustained efforts and innovations of leading biotech companies such as InMed Pharmaceuticals, Inc. (IMLFF) (InMed Profile), GW Pharmaceuticals plc (GWPH), Zynerba Pharmaceuticals, Inc. (ZYNE), AXIM® Biotechnologies, Inc. (AXIM) and…

Continue Reading

TuesdayMar 14, 2017 7:30 pm

InMed Pharmaceuticals, Inc. (IMLFF) Starts Presentation at 29th Annual ROTH Conference

InMed Pharmaceuticals (OTC: IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver. For more information, visit the company’s website at www.inmedpharma.com. About HempWireNews HempWireNews (HWN) provides news aggregation and syndication, enhanced press release services and a full array…

Continue Reading

TuesdayMar 14, 2017 4:00 pm

Intec Pharma Ltd. (NASDAQ: NTEC) Starts Presentation at 29th Annual ROTH Conference

Intec Pharma (NASDAQ: NTEC) is a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of drugs by utilizing an efficient gastric retention and specific release mechanism. The company's product pipeline currently includes three product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, currently in phase III; Accordion Pill Zaleplon; and an Accordion Pill that is being developed for the prevention and treatment of gastroduodenal and small bowel ulcers induced by Nonsteroidal Anti-Inflammatory Drugs. In addition,…

Continue Reading

TuesdayMar 14, 2017 10:41 am

India Globalization Capital, Inc. (NYSE: IGC) is “One to Watch”

India Globalization Capital, Inc. (NYSE MKT: IGC) is a first mover in developing a portfolio of products using cannabis-based “combination therapies” for the treatment of pain and other conditions. The national cost of health care due to pain ranges from $560 billion to $635 billion. In addition, the health care cost attributed to the abuse of prescription opioids, closely related to pain, is approximately $25 billion. IGC’s patent filing (IGC-501) is a cannabis-based formulation addressing neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques. The Company anticipates commencing clinical trials, and hopes that through its…

Continue Reading

MondayMar 13, 2017 4:00 pm

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) Starts Presentation at 29th Annual Roth Conference

Zynerba Pharmaceuticals (NASDAQ: ZYNE) is a specialty pharmaceutical company that focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. The company’s product candidates include ZYN002, which is in Phase I clinical trial for the treatment of refractory epilepsy, Fragile X syndrome, and osteoarthritis; and ZYN001 that is in preclinical stage for the treatment of fibromyalgia and peripheral neuropathic pain. For more information, visit the company’s website at www.zynerba.com. About HempWireNews HempWireNews (HWN) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution…

Continue Reading

HempWireNews Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722